

## News Release

Company name: H.U. Group Holdings, Inc.  
 Representative: Shigekazu Takeuchi, Director, President and Group CEO  
 Securities code: 4544 First Section, Tokyo Stock Exchange


### Launch of the Reagent for Research for the Detection of IgG Antibodies Targeting the SARS-CoV-2 N-protein

**Tokyo, Japan, July 30, 2021** --- H.U. Group Holdings Inc. today announced that its wholly-owned subsidiary, Fujirebio Inc. (President & CEO: Takeshi Fujita; Head Office: Shinjuku-ku, Tokyo; hereinafter "Fujirebio"), launched on July 30 a research assay reagent for IgG antibodies targeting the N (nucleocapsid) protein of the SARS-CoV-2, under the product name SARS-CoV-2 N-IgG (IC).

The reagent is dedicated for use with the fully automated chemiluminescent enzyme immunoassay systems LUMIPULSE® G1200 and LUMIPULSE® G600 II produced by Fujirebio.

H.U. Group will continue working to develop reagents for SARS-CoV-2 antibody tests.

#### Product Overview

Product Name	SARS-CoV-2 N-IgG (IC)	
Antibodies to be detected	IgG antibodies targeting the nucleocapsid protein (N-protein)	
Launch date	July 30, 2021	
Supported devices	LUMIPULSE G1200	LUMIPULSE G600 II
Processing capacity	120 tests/hour	60 tests/hour
Test duration	Approx. 25 min.	
Product Image		

**Contacts:**

For medical institutions

Fujirebio Inc. Call Center Phone: 0120-292-832 (toll-free in Japan only weekdays 08:00–20:00)

For media:

Public Relations Section, Public Relations/CSR Dept.

Phone: +81-3-6279-0884

Email: [pr@hugp.com](mailto:pr@hugp.com)

For investors and analysts:

IR/SR Dept.

Phone: +81-3-5909-3337

Email: [ir@hugp.com](mailto:ir@hugp.com)